Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)β’ Click on a phase to view related trials
Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Biophytis
- Target Recruit Count
- 238
- Registration Number
- NCT04472728
- Locations
- πΊπΈ
Abrazo Health, Phoenix, Arizona, United States
πΊπΈUniversity of California, Irvine, Irvine, California, United States
πΊπΈBarnum Medical Research, Inc. 1029 Keyser Ave Suite H, Natchitoches, Louisiana, United States
A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)
- Conditions
- SarcopeniaGait Disorders in Old AgeMuscle Weakness
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Biophytis
- Target Recruit Count
- 233
- Registration Number
- NCT03452488
- Locations
- πΊπΈ
Advanced Clinical Research, West Jordan, Utah, United States
πΊπΈSC Clinical Research, Inc, Garden Grove, California, United States
πΊπΈCalifornia Research Foundation, San Diego, California, United States
An OBServational Clinical Trial (SARA-OBS) in Sarcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over
- Conditions
- Muscle WeaknessSarcopeniaGait Disorders in Old Age
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Biophytis
- Target Recruit Count
- 218
- Registration Number
- NCT03021798
- Locations
- πΊπΈ
Institut On Aging, Gainesville, Florida, United States
πΊπΈJean Mayer USDA Human Nutrition research Center on Aging Tufts University, Boston, Massachusetts, United States
πΊπΈColumbia University New York, New York, New York, United States
News
Stargardt Disease Pipeline Shows Promising Progress with Multiple Gene Therapies Advancing to Late-Stage Trials
Ocugen's OCU410ST gene therapy has received FDA approval to launch a Phase 2/3 pivotal confirmatory trial for treating all forms of Stargardt disease, with the potential to serve as the foundation for a biologics license application.
Sarcopenia Pipeline Shows Robust Growth with 18+ Pharma Companies Developing Novel Therapies
β’ The sarcopenia market remains largely untapped with no approved drug therapies in major markets, despite significant unmet medical needs in an aging global population. β’ DelveInsight reports 18+ pharmaceutical companies actively developing 20+ pipeline drugs for sarcopenia, with promising candidates including Biophytis' BIO101, TNF Pharmaceuticals' MYMD-1, and Epirium Bio's MF-300. β’ Recent regulatory milestones include Fast Track Designation for Lipocine's LPCN1148 for sarcopenia in patients with decompensated cirrhosis, signaling increased recognition of sarcopenia as a distinct clinical condition.
Biophytis Reports Promising Results: BIO101 and GLP-1 Combination Restores Muscle Strength in Obesity
New preclinical data shows that combining BIO101 with GLP-1 receptor agonists significantly improved mobility and grip strength in diet-induced obese mice, addressing a critical gap in obesity treatment.
Novavax Launches Clinical Trial for JN.1 Subvariant COVID-19 Vaccine
Novavax initiates a new clinical trial to evaluate the safety and immunogenicity of its JN.1 subvariant vaccine (NVX CoV2705) with Matrix-M adjuvant. The study will compare results with the previously authorized NVX-CoV2601 vaccine, marking a significant step in addressing emerging COVID-19 variants.
Biophytis Presents BIO101 Obesity Program Data at SCWD International Congress, Plans Phase 2 Trial
Biophytis presented its OBA program featuring BIO101 (20-hydroxyecdysone) at the 17th SCWD International Congress, highlighting its potential to mitigate muscle loss induced by GLP-1RA therapies in obese patients.
Biophytis Receives FDA Approval for Phase 2 Obesity Trial of BIO101 to Address Muscle Loss in GLP-1 Therapy
Biophytis has received FDA IND approval for a phase 2 clinical study evaluating BIO101 (20-hydroxyecdysone) in obesity patients to preserve muscle strength and function.
Biophytis Receives FDA Authorization for First-Ever Phase 3 Sarcopenia Trial
Biophytis has received FDA authorization to launch SARA-31, marking the first-ever Phase 3 clinical trial specifically designed to treat sarcopenia, an age-related muscle wasting condition.
Biophytis Receives Regulatory Approval to Launch First-Ever Phase 3 Trial for Sarcopenia Treatment
Biophytis has received positive regulatory opinion from Belgian authorities to conduct SARA-31, marking the first phase 3 study ever launched in sarcopenia, a condition affecting over 30 million patients worldwide.